GlassScriptPhysician profile
Elias S Abboud
NPI 1043291222
$4,814.81
in general payments reported to CMS, 2019-2025
27 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $356 · 2021: $329 · 2022: $343 · 2023: $565 · 2024: $833 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,276.75 | 2019-2025 | Rocklatan, Precision 1, Precision7 |
| Bausch & Lomb Americas INC. | $708.73 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sight Sciences, INC. | $269.48 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $231.89 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $225.53 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $224.89 | 2022-2025 | Oxervate |
| Allergan, INC. | $189.92 | 2019-2021 | |
| Optos, INC. | $142.42 | 2019-2020 | |
| Biotissue Holdings INC. | $137.00 | 2025 | |
| Astellas Pharma US INC | $125.77 | 2023 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Abbvie INC. | $115.09 | 2022-2025 | Durysta, Lumigan |
| Horizon Therapeutics Plc | $113.03 | 2023 | Tepezza |
| Lkc Technologies, INC. | $110.89 | 2024 | |
| Harrow Eye, LLC | $110.17 | 2025 | Vevye |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $106.53 | 2019 | |
| Aerie Pharmaceuticals, INC. | $104.82 | 2019 | |
| Glaukos Corporation | $104.12 | 2025 | Istent, Idosetr |
| Genzyme Corporation | $83.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.64 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.55 | 2020-2021 | |
| Oyster Point Pharma, INC. | $53.27 | 2024 | Ryzumvi, Tyrvaya |
| Amgen INC. | $29.91 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $28.65 | 2025 | Tecnis Simplicity |
| Thea Pharma INC. | $21.41 | 2025 | Iyuzeh |
| Rxsight INC | $19.44 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.